Nicholas Company Inc. Raises Position in Medtronic PLC $MDT

Nicholas Company Inc. grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 38.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,815 shares of the medical technology company’s stock after acquiring an additional 19,740 shares during the period. Nicholas Company Inc.’s holdings in Medtronic were worth $6,802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Corundum Trust Company INC bought a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC grew its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic during the 3rd quarter valued at $29,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MDT shares. Evercore set a $106.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a research report on Thursday, April 9th. Jefferies Financial Group reissued a “hold” rating and set a $95.00 price objective on shares of Medtronic in a research report on Thursday, April 23rd. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Finally, Mizuho cut their price objective on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Trading Down 0.2%

Shares of Medtronic stock opened at $76.03 on Monday. The company has a market capitalization of $97.62 billion, a P/E ratio of 21.18, a P/E/G ratio of 1.81 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a fifty day moving average of $87.26 and a 200 day moving average of $94.43. Medtronic PLC has a fifty-two week low of $75.91 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.7%. Medtronic’s payout ratio is presently 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE Mark for its Stealth AXiS system, adding to the earlier FDA approval and expanding the next-generation planning, navigation, and robotics platform into Europe. That strengthens the company’s surgical robotics and imaging portfolio and could support future procedure growth. Following FDA Approval, Medtronic (MDT) Receives CE Mark For Stealth AXiS System
• Positive Sentiment: Medtronic expanded its neuromodulation business by launching Adaptive Deep Brain Stimulation for Parkinson’s disease in India, which broadens its reach in a large and growing market and highlights continued innovation in its neurological therapies segment. Medtronic Expands Neuromodulation Reach With Adaptive DBS Launch In India
• Neutral Sentiment: Several articles focused on whether MDT looks attractive after recent share-price weakness and whether Wall Street’s bullish analyst views make the stock worth buying. These pieces can keep attention on the name, but they did not add new fundamental data. Is Medtronic (MDT) Offering Value After Recent Share Price Weakness? Is It Worth Investing in Medtronic (MDT) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Third-party “best stocks” and retiree-income articles also mentioned Medtronic, which may provide some investor visibility, but these are largely promotional and not direct company-specific catalysts. 3 Healthcare Stocks Every Retiree Should Consider Better Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).